Croma-Pharma
Tomas Toth has a diverse work experience spanning several industries. Tomas started their career in 1995 with a temporary position at Dresdner Bank. In 1996, they worked in procurement at Volkswagen. Tomas then transitioned to the legal field, working as a legal assistant at Mondl Trummer Thomas & Partner Rechtsanwälte GmbH in Kooperation mit Lowels from 2002 to 2004, and as a junior lawyer at Hule Bachmayer Heyda Nordberg from 2004 to 2008. Tomas then moved into management roles at Mondi AG, where they served as a management contracts expert from 2008 to 2013. Tomas then joined Mondi Halle GmbH as an HR manager from 2013 to 2017. Currently, they hold the position of Global Human Resources Director at CROMA-PHARMA, starting in 2017.
Tomas Toth's education history includes obtaining a Magister degree in Rechtswissenschaften (Law) from the University of Vienna. In addition, they received a certification of Diplomnostrifizierung from Komenius Universität Bratislava in June 2004. Tomas also holds a Magisterbescheid from the University of Wien. No specific start or end years are provided for their education at the University of Vienna.
This person is not in any teams
This person is not in any offices
Croma-Pharma
4 followers
Croma is a global player in the minimally invasive aesthetics market and a leading European manufacturer of premium quality hyaluronic acid syringes. The company offers a comprehensive and innovative aesthetics portfolio including botulinum toxin, fillers, lifting threads and biostimulators complemented by its own skincare brand. Founded in 1976 by a pharmacist couple, Croma-Pharma GmbH is a family company headquartered in Austria where it also operates its manufacturing plant. With 550 employees, 13 subsidiaries in Europe and Brazil, two joint ventures and 60 exclusive export partners, it distributes its products in 80 markets globally, including the US, Canada, China, Australia and New Zealand. It also operates as a contract manufacturer in orthopaedics and ophthalmology. For more information please visit cromapharma.com.